- Home
- XLO
as 07-08-2024 3:36pm EST
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 33.5M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 491.3K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.49 - $2.94 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 150.00% |
Stock Insider Trading Activity of Xilio Therapeutics Inc. (XLO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | XLO | 10% Owner | Apr 2 '24 | Buy | $0.76 | 485,250 | $368,790.00 | 7,345,473 | SEC Form 4 |
| Atlas Venture Fund XI, L.P. | XLO | 10% Owner | Feb 8 '24 | Sell | $0.64 | 733 | $469.12 | 2,019,563 | SEC Form 4 |
| Atlas Venture Fund XI, L.P. | XLO | 10% Owner | Feb 8 '24 | Sell | $0.64 | 267 | $170.88 | 734,546 | SEC Form 4 |
| Atlas Venture Fund XI, L.P. | XLO | 10% Owner | Jan 11 '24 | Sell | $0.87 | 1,566 | $1,362.42 | 2,021,836 | SEC Form 4 |
| Atlas Venture Fund XI, L.P. | XLO | 10% Owner | Jan 11 '24 | Sell | $0.87 | 569 | $495.03 | 735,373 | SEC Form 4 |
| Atlas Venture Fund XI, L.P. | XLO | 10% Owner | Jan 11 '24 | Sell | $0.83 | 1,540 | $1,278.20 | 2,020,296 | SEC Form 4 |
| Atlas Venture Fund XI, L.P. | XLO | 10% Owner | Jan 11 '24 | Sell | $0.83 | 560 | $464.80 | 734,813 | SEC Form 4 |
Latest Xilio Therapeutics Inc. News
XLO Breaking Stock News: Dive into XLO Ticker-Specific Updates for Smart Investing
Simply Wall St.
9 days ago
Can Xilio Therapeutics (NASDAQ:XLO) Afford To Invest In Growth?
GlobeNewswire
25 days ago
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors
CNW Group
a month ago
Start Proud Opens the Market
Associated Press Finance
a month ago
Will recreational pot go on sale soon in Ohio? Medical marijuana stores can now apply to sell it
Business Wire
a month ago
Form 8.3 - Darktrace plc
Investor's Business Daily
a month ago
Dow Jones Trims Losses As Yields Spike On Jobs Data; GameStop Dives
Yahoo Finance Video
a month ago
May jobs reports signals Fed's soft landing: US Labor Secretary
Business Wire
a month ago
NICE to Webcast Financial Analyst and Investor Day at Interactions 2024
Share on Social Networks:
Disclaimer
The information presented on this page, "XLO Xilio Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.